ImmuneWalk Therapeutics Company Profile, Contacts & Intelligence

ImmuneWalk Therapeutics Overview

ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.

Headquarters

Pearl River, New York, United States

Industry

Biotechnology Research

Founded

2023

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

ImmuneWalk Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

ImmuneWalk Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

ImmuneWalk Therapeutics Workforce Composition

Seniority breakdown across 4 visible profiles.

Compare Similar Companies to ImmuneWalk Therapeutics

Explore companies in related markets and compare their industry and employee estimates.